Do analysts rate STVN or FTRE?

Fortrea has a consensus price target of $20.75, indicating a potential upside of 12.59%. Given Fortrea's higher possible upside, analysts plainly believe Fortrea is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00 Fortrea 1 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media prefer STVN or FTRE?

In the previous week, Stevanato Group had 7 more articles in the media than Fortrea. MarketBeat recorded 14 mentions for Stevanato Group and 7 mentions for Fortrea. Stevanato Group's average media sentiment score of 0.39 beat Fortrea's score of -0.27 indicating that Stevanato Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fortrea 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TXG or FTRE more profitable?

Fortrea has a net margin of -3.18% compared to 10x Genomics' net margin of -12.18%. Fortrea's return on equity of 10.72% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets 10x Genomics -12.18% -9.41% -7.31% Fortrea -3.18% 10.72% 2.17%

Does the media refer more to TXG or FTRE?

In the previous week, 10x Genomics had 10 more articles in the media than Fortrea. MarketBeat recorded 17 mentions for 10x Genomics and 7 mentions for Fortrea. 10x Genomics' average media sentiment score of 0.61 beat Fortrea's score of -0.27 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 6 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Fortrea 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer FTRE or TWST?

In the previous week, Twist Bioscience had 24 more articles in the media than Fortrea. MarketBeat recorded 31 mentions for Twist Bioscience and 7 mentions for Fortrea. Twist Bioscience's average media sentiment score of 0.36 beat Fortrea's score of -0.27 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Twist Bioscience 7 Very Positive mention(s) 6 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is FTRE or SHC more profitable?

Sotera Health has a net margin of 13.44% compared to Fortrea's net margin of -3.18%. Sotera Health's return on equity of 40.12% beat Fortrea's return on equity. Company Net Margins Return on Equity Return on Assets Fortrea -3.18% 10.72% 2.17% Sotera Health 13.44% 40.12% 7.55%

Does the media prefer FTRE or SHC?

In the previous week, Sotera Health had 12 more articles in the media than Fortrea. MarketBeat recorded 19 mentions for Sotera Health and 7 mentions for Fortrea. Sotera Health's average media sentiment score of 0.89 beat Fortrea's score of -0.27 indicating that Sotera Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sotera Health 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CAI or FTRE?

In the previous week, Caris Life Sciences had 11 more articles in the media than Fortrea. MarketBeat recorded 18 mentions for Caris Life Sciences and 7 mentions for Fortrea. Caris Life Sciences' average media sentiment score of 0.79 beat Fortrea's score of -0.27 indicating that Caris Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 9 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortrea 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Fortrea (FTRE) Competitors

$18.43 +0.74 (+4.18%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$18.42 0.00 (-0.03%)

As of 08/7/2026 07:34 PM Eastern

Compare

FTRE vs. STVN, TXG, TWST, SHC, and CAI

Should you buy Fortrea stock or one of its competitors? MarketBeat compares Fortrea with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fortrea include Stevanato Group (STVN), 10x Genomics (TXG), Twist Bioscience (TWST), Sotera Health (SHC), and Caris Life Sciences (CAI). These companies are all part of the "life sciences tools & services" industry.

How does Fortrea compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Fortrea (NASDAQ:FTRE) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

Stevanato Group has a net margin of 10.99% compared to Fortrea's net margin of -3.18%. Fortrea's return on equity of 10.72% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.99%	10.43%	6.16%
Fortrea	-3.18%	10.72%	2.17%

Stevanato Group has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	4.58	€158.21M	€0.56	36.26
Fortrea	$2.68B	0.65	-$986.20M	-$0.91	N/A

Stevanato Group has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, Fortrea has a beta of 1.99, meaning that its share price is 99% more volatile than the broader market.

In the previous week, Stevanato Group had 7 more articles in the media than Fortrea. MarketBeat recorded 14 mentions for Stevanato Group and 7 mentions for Fortrea. Stevanato Group's average media sentiment score of 0.39 beat Fortrea's score of -0.27 indicating that Stevanato Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	4 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortrea	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fortrea has a consensus price target of $20.75, indicating a potential upside of 12.59%. Given Fortrea's higher possible upside, analysts plainly believe Fortrea is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Stevanato Group beats Fortrea on 10 of the 15 factors compared between the two stocks.

How does Fortrea compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Fortrea (NASDAQ:FTRE) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

10x Genomics has higher earnings, but lower revenue than Fortrea. 10x Genomics is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	10.28	-$43.54M	-$0.17	N/A
Fortrea	$2.68B	0.65	-$986.20M	-$0.91	N/A

Fortrea has a net margin of -3.18% compared to 10x Genomics' net margin of -12.18%. Fortrea's return on equity of 10.72% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.41%	-7.31%
Fortrea	-3.18%	10.72%	2.17%

10x Genomics has a beta of 2.03, meaning that its stock price is 103% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

84.7% of 10x Genomics shares are held by institutional investors. 8.8% of 10x Genomics shares are held by company insiders. Comparatively, 0.7% of Fortrea shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

10x Genomics presently has a consensus target price of $34.83, suggesting a potential downside of 33.05%. Fortrea has a consensus target price of $20.75, suggesting a potential upside of 12.59%. Given Fortrea's stronger consensus rating and higher possible upside, analysts plainly believe Fortrea is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, 10x Genomics had 10 more articles in the media than Fortrea. MarketBeat recorded 17 mentions for 10x Genomics and 7 mentions for Fortrea. 10x Genomics' average media sentiment score of 0.61 beat Fortrea's score of -0.27 indicating that 10x Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	6 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Fortrea	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

10x Genomics and Fortrea tied by winning 8 of the 16 factors compared between the two stocks.

How does Fortrea compare to Twist Bioscience?

Fortrea (NASDAQ:FTRE) and Twist Bioscience (NASDAQ:TWST) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

In the previous week, Twist Bioscience had 24 more articles in the media than Fortrea. MarketBeat recorded 31 mentions for Twist Bioscience and 7 mentions for Fortrea. Twist Bioscience's average media sentiment score of 0.36 beat Fortrea's score of -0.27 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Twist Bioscience	7 Very Positive mention(s)	6 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Fortrea presently has a consensus target price of $20.75, suggesting a potential upside of 12.59%. Twist Bioscience has a consensus target price of $98.30, suggesting a potential downside of 15.02%. Given Fortrea's higher probable upside, equities analysts clearly believe Fortrea is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Twist Bioscience has lower revenue, but higher earnings than Fortrea. Twist Bioscience is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.68B	0.65	-$986.20M	-$0.91	N/A
Twist Bioscience	$431.80M	16.80	-$77.67M	-$2.22	N/A

Fortrea has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

Fortrea has a net margin of -3.18% compared to Twist Bioscience's net margin of -31.66%. Fortrea's return on equity of 10.72% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Twist Bioscience	-31.66%	-28.64%	-19.94%

Summary

Fortrea and Twist Bioscience tied by winning 7 of the 14 factors compared between the two stocks.

How does Fortrea compare to Sotera Health?

Fortrea (NASDAQ:FTRE) and Sotera Health (NASDAQ:SHC) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

Fortrea has a beta of 1.99, meaning that its share price is 99% more volatile than the broader market. Comparatively, Sotera Health has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

91.0% of Sotera Health shares are owned by institutional investors. 0.7% of Fortrea shares are owned by company insiders. Comparatively, 15.4% of Sotera Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sotera Health has a net margin of 13.44% compared to Fortrea's net margin of -3.18%. Sotera Health's return on equity of 40.12% beat Fortrea's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Sotera Health	13.44%	40.12%	7.55%

Fortrea currently has a consensus target price of $20.75, indicating a potential upside of 12.59%. Sotera Health has a consensus target price of $21.50, indicating a potential upside of 14.00%. Given Sotera Health's stronger consensus rating and higher possible upside, analysts clearly believe Sotera Health is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Sotera Health has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.68B	0.65	-$986.20M	-$0.91	N/A
Sotera Health	$1.16B	4.62	$77.94M	$0.41	46.00

In the previous week, Sotera Health had 12 more articles in the media than Fortrea. MarketBeat recorded 19 mentions for Sotera Health and 7 mentions for Fortrea. Sotera Health's average media sentiment score of 0.89 beat Fortrea's score of -0.27 indicating that Sotera Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sotera Health	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sotera Health beats Fortrea on 14 of the 16 factors compared between the two stocks.

How does Fortrea compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Fortrea (NASDAQ:FTRE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Caris Life Sciences has a net margin of 10.62% compared to Fortrea's net margin of -3.18%. Caris Life Sciences' return on equity of 18.77% beat Fortrea's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	10.62%	18.77%	9.34%
Fortrea	-3.18%	10.72%	2.17%

In the previous week, Caris Life Sciences had 11 more articles in the media than Fortrea. MarketBeat recorded 18 mentions for Caris Life Sciences and 7 mentions for Fortrea. Caris Life Sciences' average media sentiment score of 0.79 beat Fortrea's score of -0.27 indicating that Caris Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	9 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortrea	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Caris Life Sciences has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	7.91	-$68.09M	$0.36	63.17
Fortrea	$2.68B	0.65	-$986.20M	-$0.91	N/A

Caris Life Sciences has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Fortrea has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market.

Caris Life Sciences currently has a consensus price target of $26.33, indicating a potential upside of 15.80%. Fortrea has a consensus price target of $20.75, indicating a potential upside of 12.59%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Caris Life Sciences is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Caris Life Sciences beats Fortrea on 12 of the 14 factors compared between the two stocks.

Get Fortrea News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FTRE vs. The Competition

Export

Metric	Fortrea	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.75B	$9.57B	$7.03B	$13.02B
Dividend Yield	N/A	1.45%	2.58%	10.20%
P/E Ratio	-20.25	63.07	271.36	25.19
Price / Sales	0.65	105.68	603.79	89.40
Price / Cash	1.86	26.16	71.81	50.72
Price / Book	3.34	38.45	13.25	6.22
Net Income	-$986.20M	$56.66B	$3.45B	$342.66M
7 Day Performance	-3.86%	5.17%	4.67%	4.41%
1 Month Performance	4.30%	0.37%	-1.28%	-1.10%
1 Year Performance	180.09%	22.07%	77.33%	23.99%

Fortrea Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FTRE Fortrea	2.935 of 5 stars	$18.43 +4.2%	$20.75 +12.6%	+180.1%	$1.75B	$2.68B	N/A	14,300	Analyst Downgrade Insider Trade
STVN Stevanato Group	2.9474 of 5 stars	€20.70 +0.6%	N/A	-13.6%	€6.27B	€1.34B	35.09	6,010	Gap Down
TXG 10x Genomics	1.8627 of 5 stars	$47.01 -0.6%	$32.08 -31.8%	+323.4%	$6.00B	$642.82M	N/A	1,240	Trending News Earnings Report Analyst Forecast
TWST Twist Bioscience	1.4407 of 5 stars	$101.06 +10.4%	$95.30 -5.7%	+351.1%	$5.70B	$376.57M	N/A	990	News Coverage Earnings Report Analyst Forecast High Trading Volume
SHC Sotera Health	4.0588 of 5 stars	$17.99 +0.7%	$20.25 +12.6%	+35.0%	$5.09B	$1.16B	43.88	3,000	Trending News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FTRE) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fortrea (FTRE) Competitors

FTRE vs. STVN, TXG, TWST, SHC, and CAI

How does Fortrea compare to Stevanato Group?

Summary

How does Fortrea compare to 10x Genomics?

Summary

How does Fortrea compare to Twist Bioscience?

Summary

How does Fortrea compare to Sotera Health?

Summary

How does Fortrea compare to Caris Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTRE vs. The Competition

Fortrea Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fortrea (FTRE) Competitors

FTRE vs. STVN, TXG, TWST, SHC, and CAI

How does Fortrea compare to Stevanato Group?

Is STVN or FTRE more profitable?

Which has stronger valuation & earnings, STVN or FTRE?

Which has more volatility & risk, STVN or FTRE?

Does the media prefer STVN or FTRE?

Do analysts rate STVN or FTRE?

Summary

How does Fortrea compare to 10x Genomics?

Which has better earnings & valuation, TXG or FTRE?

Is TXG or FTRE more profitable?

Which has more volatility & risk, TXG or FTRE?

Do institutionals and insiders hold more shares of TXG or FTRE?

Do analysts prefer TXG or FTRE?

Does the media refer more to TXG or FTRE?

Summary

How does Fortrea compare to Twist Bioscience?

Does the media prefer FTRE or TWST?

Do analysts recommend FTRE or TWST?

Which has stronger valuation and earnings, FTRE or TWST?

Which has more volatility & risk, FTRE or TWST?

Is FTRE or TWST more profitable?

Summary

How does Fortrea compare to Sotera Health?

Which has more risk & volatility, FTRE or SHC?

Do institutionals & insiders have more ownership in FTRE or SHC?

Is FTRE or SHC more profitable?

Do analysts recommend FTRE or SHC?

Which has preferable earnings & valuation, FTRE or SHC?

Does the media prefer FTRE or SHC?

Summary

How does Fortrea compare to Caris Life Sciences?

Is CAI or FTRE more profitable?

Does the media refer more to CAI or FTRE?

Which has stronger valuation and earnings, CAI or FTRE?

Which has more risk and volatility, CAI or FTRE?

Do analysts prefer CAI or FTRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTRE vs. The Competition

Fortrea Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools